Alpha Tau Medical Ltd. (DRTS)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and Scilex have yielded strong returns, including a near tripling of its $38.2M Alpha Tau Medical stake and robust loan recovery from Scilex. Alpha Tau Medical's Alpha DaRT product, with approvals in Japan and Israel and a lucrative U.S. licensing deal, offers substantial upside but faces clinical and regulatory risks.
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients achieved a complete response (CR), essentially unheard of in GBM. Alpha Tau is still severely underknown to investors, adding to its re-rating potential.
Alpha Tau Medical: A Lot Of Shots On Goal
Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT" technology overcomes prior range limitations and shows high response rates in multiple indications. This month's recent Tolmar partnership brings $35M in upfront capital and potential milestones, supporting DRTS's cash runway through 2027 amid ongoing trials.
Alpha Tau Medical Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| AB Anthony Bruccoleri Equitable Holdings Inc. | 10,000 | $25,100 | $142,500 | $117,400 | 467.73% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 16,500 | $207,570 | $237,765 | $30,195 | 14.55% |
 Christoph Von Dem Bussche Financial Guidance Group Inc. | 20,000 | $78,931.45 | $288,200 | $209,268.55 | 265.13% |
 Sue Oleari Trifecta Capital Advisors LLC | 9,700 | $48,015 | $139,777 | $91,762 | 191.11% |
 Kevin Bresler TD Waterhouse Canada Inc. | 2,568 | $11,119 | $30,276.72 | $19,157.72 | 172.3% |
Alpha Tau Medical Ltd. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LS Lukas Shumway Barclays | 7,053.98 | $94,499.77 | $101,788.88 | $7,289.11 | 7.71% |
Alpha Tau Medical Ltd. (DRTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alpha Tau Medical Ltd. ever had a stock split?
Alpha Tau Medical Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Uzi Sofer CEO | NASDAQ (CM) Exchange | 55302T102 CUSIP |
| IL Country | 112 Employees | - Last Dividend | - Last Split | 8 Mar 2021 IPO Date |
Overview
Alpha Tau Medical Ltd. is a pioneering force in the field of oncology therapeutics, currently in the clinical-stage of developing a revolutionary treatment known as diffusing alpha-emitters radiation therapy (Alpha DaRT). With its focus on targeting solid cancers, the company's research and development efforts span across both Israel and the United States. Established in 2015 and having its headquarters in Jerusalem, Israel, Alpha Tau Medical Ltd. is committed to advancing the fight against cancer through its innovative approach to radiation therapy. By leveraging the unique properties of alpha-emitters, the company aims to provide new hope and solutions for patients battling various forms of solid tumors.
Products and Services
Alpha Tau Medical Ltd. is centered around its proprietary Alpha DaRT technology, which is currently being evaluated through clinical trials and preclinical studies for its efficacy in treating a wide range of solid tumors:
- Skin, Oral, Pancreatic, Prostate, Lung, Liver, and Breast Cancers: These are at the forefront of the company’s clinical trials utilizing Alpha DaRT technology, showcasing its versatility and potential in treating a diverse array of solid tumor types.
- Brain and Other Cancers: Alpha Tau Medical is extending its research to include preclinical or pending clinical studies for brain and various other forms of cancer, highlighting the expansive scope of Alpha DaRT's applicability and its potential to offer benefits across a broader spectrum of oncological challenges.
- Hepatic Cell Carcinoma, Glioblastoma Multiforme, Lung Cancer, and More: The company is also engaged in preclinical studies targeting these specific types of cancer, underscoring its commitment to exploring Alpha DaRT's effectiveness in combating even the most challenging and aggressive forms of solid tumors.
